Antiretroviral Therapy
Drug-dependent HIV-1 variant emerges during T20 fusion inhibitor therapy
Published in Blood Weekly, January 20th, 2005
According to a study from the Netherlands, "The fusion inhibitor T20 belongs to a new class of anti-human immunodeficiency virus type 1 (HIV-1) drugs designed to block entry of the virus into the host cell.
"However, the success of T20 has met with the inevitable emergence of drug-resistant HIV-1 variants. We describe an evolutionary pathway taken by HIV-1 to escape from the selective pressure of T20 in a treated patient."
"Besides the appearance of T20-resistant variants," wrote C.E. Baldwin and coworkers, "we report for the first time the emergence of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2005-01-20)
More Articles from Blood Weekly
- Embryonic Stem Cell Research
Genes identified that are enriched in embryonic stem cells - Neural Stem Cell Transplantation
Neural SCT promotes long-term functional recovery after traumatic brain injury - Protein Signaling
Transcriptional activity of Smad proteins in development monitored in vivo - Tissue Engineering
Cartilage-like tissue engineered with mesenchymal SCs and silk protein scaffolds - Wound Healing
BM-derived cells contribute to epithelial engraftment during wound healing - Antiretroviral Therapy
Novel sesterterpenes isolated from Madagascan sponges inhibit HIV-1 RT - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
